Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis

David F. McDermott,Ruchit Shah,Komal Gupte-Singh,J Sabater,Linlin Luo,Marc F. Botteman,Sumati Rao,Meredith M. Regan,Michael B. Atkins

Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis

2019

David F. McDermott
Ruchit Shah
Komal Gupte-Singh
J Sabater
Linlin Luo
Marc F. Botteman
Sumati Rao
Meredith M. Regan
Michael B. Atkins

Purpose To compare the quality-adjusted survival of nivolumab plus ipilimumab combination and nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma based on a minimum 36-month follow-up from the CheckMate 067 trial.

Keywords:

Nivolumab
Melanoma
Ipilimumab
Medicine
Physical therapy
Checkmate
quality adjusted survival
Toxicity
therapy naive
Oncology
advanced melanoma
Internal medicine
Quality of Life Research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations